LexDanaLexDanabeta
Inventor

Charles Z. Ding

Inventor
Shanghai, CN

Overview

46→
Patents
1996–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 46 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
C07DHeterocyclic compounds33%
A61KPreparations for medical, dental or toiletry purposes19%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium5%
C07BGeneral methods of organic chemistry2%
Y02ATechnologies for adaptation to climate change2%
C07CAcyclic or carbocyclic compounds2%
A01NPreservation of bodies of humans or animals or plants or parts thereof1%
G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes1%
Y02PClimate change mitigation technologies in the production or processing of goods1%
PatentTitleYear
10,851,071M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof202010,774,081Indolo substituted piperidine compound as estrogen receptor down-regulator202010,738,051b-lactamase inhibitors202010,676,4741,6-naphthyridine derivatives as CDK4/6 inhibitor202010,654,868Dihydropyrazole azepine compound serving as Akt inhibitor202010,626,107Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor202010,617,690JAK inhibitor202010,548,883Benzotriazole-derived a and b-unsaturated amide compound used as TGF-b RI inhibitor202010,519,143Substituted-indole-compounds as estrogen receptor down-regulators201910,508,103Benzimidazole-linked indole compound acting as novel divalent IAP antagonist201910,501,443Pyridone compound as c-met inhibitor201910,494,373Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor201910,428,073Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof201910,227,362Anti-pulmonary tuberculosis nitroimidazole derivative201910,134,040Systems and methods for large-scale testing activities discovery201810,093,656Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor201810,035,792Resorcinol derivative as HSP90 inhibitor20189,969,719Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug20189,751,898'Boron-containing small molecules'20178,703,742'Boron-containing small molecules'20148,461,135'Boron-containing small molecules as anti-inflammatory agents'20138,343,944'Trisubstituted boron-containing molecules'20138,039,450'Boron-containing small molecules as anti-inflammatory agents'20117,951,793'Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method'20117,884,099'Quinolone carboxylic acid-substituted rifamycin derivatives'20117,678,791'Nitroheteroaryl-containing rifamycin derivatives'20107,666,864'Bicyclic nitroimidazole-substituted phenyl oxazolidinones'20107,507,757'Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method'20097,279,485'Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method'20077,256,187'Rifamycin C-11 oxime derivatives effective against drug-resistant microbes'20077,247,634'Rifamycin derivatives effective against drug-resistant microbes'20077,238,694'Rifamycin imino derivatives effective against drug-resistant microbes'20077,229,996'Rifamycin derivatives'20077,226,931'(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions'20076,916,813'(1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase'20056,875,782'Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method'20056,624,157'Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase'20036,602,883'Inhibitors of farnesyl protein transferase'20036,458,783'Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase'20026,455,523'Inhibitors of farnesyl protein transferase'20026,387,926'Inhibitors of farnesyl protein transferase'20026,156,746'1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents'20006,011,029'Inhibitors of farnesyl protein transferase'20005,869,478'Sulfonamido substituted benzopyran derivatives'19995,837,702'4-arylamino-benzopyran and related compounds'19985,547,966'Aryl urea and related compounds'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2011Patents assigned to BRISTOL MYERS SQUIBB CO (15)· patent assignee history
1996–2003Based in Plainsboro, NJ, US· patent location history
2005–2010Based in Plano, TX, US· patent location history
2007Patents assigned to CUMBRE PHARMACEUTICALS INC (5)· patent assignee history
2011–2017Patents assigned to ANACOR PHARMACEUTICALS INC (5)· patent assignee history
2011–2013Based in Palo Alto, CA, US· patent location history
2013–2017Based in San Mateo, CA, US· patent location history
2018–2020Patents assigned to MEDSHINE DISCOVERY INC (5)· patent assignee history
2018–2020Patents assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (4)· patent assignee history
2018–2020Based in Shanghai, CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BRISTOL MYERS SQUIBB CO151996–2011
ANACOR PHARMACEUTICALS INC52011–2017
CUMBRE PHARMACEUTICALS INC52007
MEDSHINE DISCOVERY INC52018–2020
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD42018–2020
Locations
LocationPatentsSpan
Shanghai, CN172018–2020
Plainsboro, New Jersey, US101996–2003
Plano, Texas, US92005–2010
San Mateo, California, US32013–2017
Palo Alto, California, US22011–2013